APM
AKBA icon

Avidity Partners Management’s Akebia Therapeutics AKBA Stock Holding History

Avidity Partners Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,324,000
Closed -$18.4M – 99
2020
Q3 		$18.4M Buy
+7,324,000
New +$64.3M 0.85% 39

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Avidity Partners Management's AKBA Position: Q4 2020 in Review

Avidity Partners Management sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 7,324,000 shares — an estimated $18.4M sold.

Avidity Partners Management first reported a position in AKBA in Q3 2020 and held it in 1 quarter. The position peaked at $18.4M in Q3 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Avidity Partners Management reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Avidity Partners Management sold 7,324,000 Akebia Therapeutics shares in Q4 2020, an estimated $18.4M.
  • Avidity Partners Management first reported a position in Akebia Therapeutics in Q3 2020 and held it in 1 quarter.
  • Avidity Partners Management's Akebia Therapeutics position peaked at $18.4M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.